The Mechanism of Action of Inclisiran for LDL-C Management in ASCVD

Pharmacy Times interviewed Norman Lepor, MD, a Los Angeles-based cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), on the burden of atherosclerotic cardiovascular disease (ASCVD) and low-density lipoprotein cholesterol (LDL-C) management.

During the discussion, Lepor explained inclisiran’s mechanism of action and how it supports LDL-C management for patients with ASCVD.